Short-Term Debt to Equity Ratio: Trevi Therapeutics (TRVI)
Trevi Therapeutics (TRVI) currently relies on grants and clinical trials while awaiting a regulatory verdict to launch sales. Primary growth is expected from the success of Haduvio in treating pulmonary fibrosis and a lack of competitors. The asset's price trajectory, where the indicator is 0.00, reflects the business dynamics. Trevi Therapeutics (TRVI) is creating a closed treatment cycle based on nalbuphine ER, which complicates the transition of patients to other therapies.
Comprehensive metric breakdowns and analytics for trevitherapeutics.com (TRVI)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Trevi Therapeutics|TRVI - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Trevi Therapeutics, Inc.|TRVI - Aggregate Debt Obligations|Debts to Book Capitalization Trevi Therapeutics Inc|TRVI - Long-Term Debt|Company Current Liabilities Trevi Therapeutics|Quick Ratio trevitherapeutics.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Trevi Pharma
For Trevi Therapeutics (TRVI), whose resilience is based on an independent biotech development cycle, the ratio of loans under one year to equity serves as an indicator of operational liquidity. This chart calculates the share of short-term liabilities within the equity structure using daily price action, allowing investors to promptly capture changes in debt load and assess the asset's financial stability during periods of market volatility.
Competitors of Trevi Therapeutics (TRVI)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Ratio CPRX|DNLI (denalitherapeutics.com) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital AMLX (Amylyx)|Praxis Corp (PRAX) - Current Liabilities to Capital|AVXL: Short-Term Debt to Equity Ratio|CBLL: Short-Term Debt to Equity|PRTA: Short-Term Debt to Capital|ALEC - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio ANNX|OMER: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|Short-Term Loans to Capital Ratio ACIU|Short-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|Ratio of Short-Term Indebtedness to Capital NMRA|Scilex Holding Co. - Short-Term Debt to Capital|Current Liabilities to Capital Tevogen Bio Inc.|alphacognition.com (ACOG) - Short-Term Debt to Equity|cogrx.com - Ratio of Short-Term Indebtedness to Capital|IKT (Inhibikase Therapeutics, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Cassava Sciences Inc|Short-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|COYA: Current Liabilities to Equity|Short-Term Debt to Capital VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Current Liabilities to Capital|ABOS: Short-Term Debt to Equity Ratio|CRVO - Short-Term Debt to Capital|ATHE (alteritytherapeutics.com) - Short-Term Debt to Equity Ratio|CLNN: Short-Term Loans to Capital Ratio|PEPG (PepGen Inc) - Short-Term Debt to Capital|jupiterneurosciences.com (JUNS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital RLMD|Short-Term Debt to Equity Ratio Annovis Bio Inc ANVS|Short-Term Debt to Equity Grace Therapeutics GRCE|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|KLTO: Short-Term Debt to Equity Ratio|NeuroSense Therapeutics - Short-Term Loans to Capital Ratio|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|MetaVia - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio NRXS|Short-Term Debt to Equity HSDT|Short-Term Debt to Capital PASG|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|ATHA: Short-Term Debt to Capital Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Current Liabilities to Capital Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Short-Term Debt to Equity Ratio|Protagenic Therapeutics, Inc. (PTIX) - Short-Term Debt to Capital|Short-Term Debt to Equity Pasithea Therapeutics Corp|CRGT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio CHRO (chromocell.com)|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|LBPH: Short-Term Debt to Capital|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity Ratio NKGN|Short-Term Debt to Equity NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Coefficient Synaptogenix Inc.|Trevena, Inc - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VIGL|WENA: Short-Term Debt to Equity Ratio|cerevel.com - Short-Term Loans to Capital Ratio